The pharmacotherapy based on interleukin-6 inhibitor (tocilizumab) in COVID-19/SCD scenarios helps control cytokine storms and immune response dysregulation based on critical hypercytokinemia, neutrophilia, and lymphocytopenia [31]. The gene discussed is IL6; the disease is COVID-19.